Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
Autor: | Volkers, A., Straatmijer, T., Duijvestein, M., Sales, A., Levran, A., Schaik, F. van, Maljaars, J., Gecse, K., Ponsioen, C., Grootjans, J., Hanzel, J., Tack, G., Jansen, J., Hoentjen, F., Boer, N. de, Marel, S. van der, Dijkstra, G., Oldenburg, B., Lowenberg, M., Meulen, A. van der, D'Haens, G., IBD Ctr Amsterdam, Dutch Initiative Crohn Colitis |
---|---|
Přispěvatelé: | Gastroenterology and Hepatology, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Tytgat Institute for Liver and Intestinal Research, Groningen Institute for Organ Transplantation (GIOT), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Gastroenterology and hepatology, Amsterdam Gastroenterology Endocrinology Metabolism |
Rok vydání: | 2022 |
Předmět: |
Hepatology
INDUCTION Remission Induction Gastroenterology Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0] Antibodies Monoclonal Humanized Inflammatory Bowel Diseases THERAPY Treatment Outcome Crohn Disease Gastrointestinal Agents Phobic Disorders inflammatory bowel disease REGISTRY Humans Colitis Ulcerative subcutaneous vedolizumab Pharmacology (medical) Prospective Studies real-world evidence Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] |
Zdroj: | Alimentary Pharmacology & Therapeutics, 56, 1044-1054 Alimentary Pharmacology and Therapeutics, 56(6), 1044-1054. Wiley-Blackwell Alimentary Pharmacology & Therapeutics, 56, 6, pp. 1044-1054 IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis 2022, ' Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases ', Alimentary Pharmacology and Therapeutics, vol. 56, no. 6, pp. 1044-1054 . https://doi.org/10.1111/apt.17153 Alimentary Pharmacology & Therapeutics, 56(6), 1044-1054. Wiley Alimentary Pharmacology and Therapeutics, 56(6), 1044-1054 Alimentary Pharmacology and Therapeutics, 56(6), 1044-1054. WILEY |
ISSN: | 0269-2813 |
Popis: | Contains fulltext : 288020.pdf (Publisher’s version ) (Open Access) BACKGROUND: Subcutaneous (SC) vedolizumab is effective in inflammatory bowel diseases (IBD) when administered after induction with two infusions. AIM: To assess the effectiveness, safety and pharmacokinetics of a switch from intravenous (IV) to SC maintenance vedolizumab in patients with IBD METHODS: In this prospective cohort study, patients with IBD who had ≥4 months IV vedolizumab were switched to SC vedolizumab. We studied the time to discontinuation of SC vedolizumab, adverse events (AEs), changes in clinical and biochemical outcomes and vedolizumab concentrations at baseline, and weeks 12 and 24. RESULTS: We included 82 patients with Crohn's disease (CD) and 53 with ulcerative colitis (UC). Eleven (13.4%) patients with CD and five (9.4%) with UC discontinued SC vedolizumab after a median of 18 (IQR 8-22) and 6 weeks (IQR 5-10), respectively. Four patients with CD switched to a different drug due to loss of response, nine switched back to IV vedolizumab due to adverse events, and three due to needle fear. Common AEs were injection site reactions (n = 15) and headache (n = 6). Median clinical and biochemical disease activity remained stable after the switch. Median serum vedolizumab concentrations increased from 19 μg/ml at the time of the switch to 31 μg/ml 12 weeks after the switch (p |
Databáze: | OpenAIRE |
Externí odkaz: |